SUMM.L

Summit Therapeutics Plc
AIM - Cancellation - Summit Therapeutics PLC
24th February 2020, 07:00
TwitterFacebookLinkedIn
To continue viewing RNS, please confirm that you are a Private Investor*

* A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:

  1. Obtains access to the information in a personal capacity;
  2. Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
  3. Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
  4. Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
  5. Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
  6. Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
RNS Number : 7948D
AIM
24 February 2020
 

NOTICE

 

24/02/2020

 

NOTICE OF CANCELLATION OF ADMISSION TO TRADING ON AIM - XLON

 

At the request of the Company the following securities have been cancelled from trading on AIM with effect from the time and date of this notice.

 

SUMMIT THERAPEUTICS PLC

213800NRW8AOMYMTBD89

ORDINARY SHARES OF 1P EACH, FULLY PAID

(BN40HZ0)(GB00BN40HZ01)

SUMT THER/PAR VTG FDP 0.01

 

If you have any queries or require further information, please contact the company's nominated adviser +44 (0)20 7213 0880.


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
AMOUASVRRRUUUAR ]]>
TwitterFacebookLinkedIn